Bibliography
- RICE KD, SPRENGLER PA: Therapeutic applications and design of mast cell tryptase inhibitors. Curr. Opin. Drug Discov. Dev. (1999) 2(5):463–474.
- ••Comprehensive, and up to date, review from the groupleading the way in designing selective tryptase inhibitors.
- PROTEUS LTD, Annual Report 1998.
- PEREIRA PJ, BERGNER A, MACEDO-RIBEIRO S: Human6-tryptase is a ring-like tetramer with active sites facing a central pore. Nature (1998) 392:306–311.
- KRISHNA MT, CHAUHAN AJ, LITTLE L et al: Effect ofinhaled APC-366 on allergen-induced bronchocon-striction and airway responsiveness to histamine in asthmatic subjects. Am J. Respir Grit Care Med. (1998) 157:A456.
- AXYS PHARMACEUTICALS, INC.: Axys Pharmaceuticals discontinues clinical study of dry powder formulation of APC-366 for asthma. Press Release (29 September 1998).
- KATZ BA, CLARK JM, FINER-MOORE JS et al.: Design of potent selective zinc-mediated serine protease inhibi-tors. Nature (1998) 391:608–612.
- •Clear exposition of the tryptase active site and how the enzyme inhibitors interact with it.
- ONO S, KUVVAHARA S, TAKEUCHI M et al.: Syntheses and evaluation of amidinobenzofuran derivatives as tryptase inhibitors. Bioorg. Med. Chem. Letts. 9(23):3285–3290.
- WRIGHT CE, HAVILL AM, MIDDLETON SC et al: Inhibi-tion of allergen-induced pulmonary responses by the selective tryptase inhibitor 1,5-bis-(4-[(3-carba-mimidoyl-benz e ne sulfo ny la mino)methyl]-phenoxy)pentane (AMG-126737). Biochem. Pharmacol (1999) 58(12):1989–1996.
Websites
- http://www.protherics.com/new/camd_tryptase_report. htm (February 2000).